1. Home
  2. GKOS vs MTH Comparison

GKOS vs MTH Comparison

Compare GKOS & MTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$107.89

Market Cap

5.4B

Sector

Health Care

ML Signal

HOLD

Logo Meritage Homes Corporation

MTH

Meritage Homes Corporation

HOLD

Current Price

$74.75

Market Cap

5.1B

ML Signal

HOLD

Company Overview

Basic Information
Metric
GKOS
MTH
Founded
1998
1985
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Homebuilding
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
5.4B
5.1B
IPO Year
2015
1988

Fundamental Metrics

Financial Performance
Metric
GKOS
MTH
Price
$107.89
$74.75
Analyst Decision
Strong Buy
Buy
Analyst Count
13
8
Target Price
$122.08
$82.88
AVG Volume (30 Days)
1.1M
862.9K
Earning Date
10-29-2025
10-28-2025
Dividend Yield
N/A
2.30%
EPS Growth
N/A
N/A
EPS
N/A
7.50
Revenue
$469,820,000.00
$6,043,594,000.00
Revenue This Year
$30.89
N/A
Revenue Next Year
$24.36
$5.61
P/E Ratio
N/A
$9.96
Revenue Growth
30.38
N/A
52 Week Low
$73.16
$59.27
52 Week High
$163.71
$96.08

Technical Indicators

Market Signals
Indicator
GKOS
MTH
Relative Strength Index (RSI) 73.56 66.68
Support Level $104.11 $72.05
Resistance Level $107.18 $74.84
Average True Range (ATR) 4.40 2.10
MACD 1.26 0.94
Stochastic Oscillator 92.97 95.51

Price Performance

Historical Comparison
GKOS
MTH

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About MTH Meritage Homes Corporation

Meritage Homes Corp is engaged as a designer and builder of single-family attached and detached homes. It has operations in three regions: West, Central, and East, comprising ten states: Arizona, California, Colorado, Texas, Florida, Georgia, North Carolina, South Carolina, Tennessee, and Utah. The company operates with two principal business segments: homebuilding and financial services. The homebuilding segments are engaged in the business of acquiring and developing land, constructing homes, marketing and selling those homes, and providing warranty and customer services, and the financial services segment offers title and escrow, mortgage, and insurance services. The company generates key revenue from the homebuilding segment.

Share on Social Networks: